There are currently two ongoing trials (phase 2 and 3) evaluating T-DXd as a first-line treatment in metastatic HER-2-positive breast cancer and one study evaluating it as a first-line treatment in HER-2-low patients (see Table 4). The gene discussed is ERBB2; the disease is breast cancer.